ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash growth accelerates

Q1 FY2026 net change in cash of $17M (cash outflow) rose 55.2% year over year, ahead of the -3.7% change in trailing-twelve-month net change in cash. Sequentially, it fell 6.8% from the prior quarter.

Context

  • Net change in cash amounted to 11.3% of revenue in FY2025, down 11.3 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +55.2% holds above the trailing-twelve-month pace of -3.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17M-6.8% QoQ
Last fiscal yearDec 2025
-$9.5M-52.9% YoY
LTMMar 2026
-$15.54M-3.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.2%——
1 year-52.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(9.5M) USD
Year-over-year change
+52.9%

Net Change in Cash vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 net change in cash of $15.54M is the 3rd largest of the 4 companies compared; the peer median is $42.08M.
  • Its year-over-year change of -3.7% is the lowest of 4, against a peer median of +258.5%.
  • Net change in cash amounts to 15.7% of revenue for SPRY, versus a peer median of 16.9%.
SPRY Competitors Peer median
Net Change in Cash for SPRY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$53.21M +1322.6%-12.7%16.9%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$42.08M +258.5%—83.7%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$15.54M -3.7%—15.7%
MNKDMannKind CorporationLTM Mar 2026$5.53M +103.8%—1.5%
Peer median (excluding SPRY) $42.08M+258.5%-12.7%16.9%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Depreciation & Amortization213K319K73K(7.18M)1.37M
Deferred Income Tax00000
Stock-Based Compensation2.83M5.84M9.24M14.53M22.1M
Change in Working Capital(356K)(12.75M)(7.33M)(1.81M)(20M)
Accounts Receivables000(8.18M)(17.21M)
Inventory000(5.95M)(21.99M)
Accounts Payables0(10.29M)(2.78M)16.43M18.88M
Other Working Capital(356K)(2.47M)(4.55M)(4.12M)306K
Other Non-Cash Items(4K)1.2M(6.88M)0(3.03M)
Operating Cash Flow(17.56M)(40.08M)(59.27M)13.55M(170.87M)
Capital Expenditures(55K)(199K)(175K)(563K)(339K)
Acquisitions (Net)00000
Purchases of Investments00(272.01M)(356.04M)(242.03M)
Sales of Investments00185M258M307M
Other Investing Activities000(7.5M)(7.86M)
Investing Cash Flow(55K)(199K)(87.18M)(106.1M)56.77M
Debt Repayment(1.82M)(8.68M)069.38M96.26M
Common Stock Issued169K570K6.9M3.02M5.68M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0198.84M002.66M
Financing Cash Flow53.16M190.73M6.9M72.4M104.6M
Effect of Forex Changes00000
Net Change in Cash35.54M150.46M(139.55M)(20.15M)(9.5M)
Free Cash Flow(17.62M)(40.28M)(59.44M)12.99M(171.21M)

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.